Vincent Cryns
Vincent Cryns | |
|---|---|
| Alma mater | Harvard College and Harvard Medical School, Boston, MA |
| Known for | cancer |
| Scientific career | |
| Institutions | University of Wisconsin-Madison |
| Website | www |
Vincent Cryns is the Chief of the Division of Endocrinology, Diabetes & Metabolism[1] at the University of Wisconsin School of Medicine and Public Health and holds the Marian A. and Rodney P. Burgenske Chair in Diabetes Research.[2][3]
Early life[edit]
Cryns attended East High School in East Amherst, New York,[4] received his bachelor's degree from Harvard College and his M.D. from Harvard Medical School in 1987.
Career[edit]
After completing residency and specialty training at Massachusetts General Hospital in Boston, Massachusetts, he became an assistant professor at Northwestern University. He later moved to Madison, Wisconsin to chair the Division of Endocrinology, Diabetes, and Metabolism at the University of Wisconsin School of Medicine and Public Health.[2]
Cryns is on the editorial board of the American Journal of Cancer Research,[5] the Journal of Drug Metabolism and Toxicology, the Journal of Signal Transduction, the Journal of Stem Cell Research and Therapy, and Molecular Endocrinology. In 2010, Cryns served as the associate editor-in-chief of the American Journal of Cancer Research.
Cryns's lab is focused on understanding apoptosis, the process by which cancer cells die, and has published on how methionine restriction sensitizes cancer cells to TRAIL receptor agonists.[6] The Cryns lab also showed that the metastasis of breast cancer to the brain and lungs is dependent upon the protein αB-crystallin.[7][8][9]
References[edit]
- ^ "UW Endocrinology, Diabetes and Metabolism".
- ^ a b "Breast Cancer Research Foundation".
- ^ "UWSMPH Directory".
- ^ "Bio - Cryns, Vincent - WEDF". www.wedf.org. Retrieved 2015-09-13.
- ^ Antin, Joseph H.; Aplin, Andrew E.; Cheng, Sheue-Yann; Emmert-Buck, Michael R.; Cryns, Vincent L.; Wang, Dengshun (2011-01-01). "American Journal of Cancer Research: Editorial Board (2011)". American Journal of Cancer Research. 1 (6): 817–822. ISSN 2156-6976. PMC 3195929. PMID 22016829.
- ^ Strekalova, Elena; Malin, Dmitry; Good, David M.; Cryns, Vincent L. (2015-06-15). "Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression". Clinical Cancer Research. 21 (12): 2780–2791. doi:10.1158/1078-0432.CCR-14-2792. ISSN 1078-0432. PMC 4470820. PMID 25724522.
- ^ Malin, Dmitry; Strekalova, Elena; Petrovic, Vladimir; Deal, Allison M.; Al Ahmad, Abraham; Adamo, Barbara; Miller, C. Ryan; Ugolkov, Andrey; Livasy, Chad (2014-01-01). "αB-crystallin: a novel regulator of breast cancer metastasis to the brain". Clinical Cancer Research. 20 (1): 56–67. doi:10.1158/1078-0432.CCR-13-1255. ISSN 1078-0432. PMC 3973485. PMID 24132917.
- ^ Malin, D.; Strekalova, E.; Petrovic, V.; Rajanala, H.; Sharma, B.; Ugolkov, A.; Gradishar, W. J.; Cryns, V. L. (2015-02-16). "ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo". Oncogene. 34 (45): 5626–34. doi:10.1038/onc.2015.12. ISSN 1476-5594. PMC 4537846. PMID 25684139.
- ^ Moyano, Jose V.; Evans, Joseph R.; Chen, Feng; Lu, Meiling; Werner, Michael E.; Yehiely, Fruma; Diaz, Leslie K.; Turbin, Dmitry; Karaca, Gamze (January 2006). "AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer". The Journal of Clinical Investigation. 116 (1): 261–270. doi:10.1172/JCI25888. ISSN 0021-9738. PMC 1323258. PMID 16395408.